209 research outputs found
Power counting with one-pion exchange
Techniques developed for handing inverse-power-law potentials in atomic
physics are applied to the tensor one-pion exchange potential to determine the
regions in which it can be treated perturbatively. In S-, P- and D-waves the
critical values of the relative momentum are less than or of the order of 400
MeV. The RG is then used to determine the power counting for short-range
interaction in the presence of this potential. In the P-and D-waves, where
there are no low-energy bound or virtual states, these interactions have
half-integer RG eigenvalues and are substantially promoted relative to naive
expectations. These results are independent of whether the tensor force is
attractive or repulsive. In the 3S1 channel the leading term is relevant, but
it is demoted by half an order compared to the counting for the effective-range
expansion with only a short-range potential. The tensor force can be treated
perturbatively in those F-waves and above that do not couple to P- or D-waves.
The corresponding power counting is the usual one given by naive dimensional
analysis.Comment: 18 pages, RevTeX (further details, explanation added
Scattering from Singular Potentials in Quantum Mechanics
In non-relativistic quantum mechanics, singular potentials in problems with
spherical symmetry lead to a Schrodinger equation for stationary states with
non-Fuchsian singularities both as r tends to zero and as r tends to infinity.
In the sixties, an analytic approach was developed for the investigation of
scattering from such potentials, with emphasis on the polydromy of the wave
function in the r variable. The present paper extends those early results to an
arbitrary number of spatial dimensions. The Hill-type equation which leads, in
principle, to the evaluation of the polydromy parameter, is obtained from the
Hill equation for a two-dimensional problem by means of a simple change of
variables. The asymptotic forms of the wave function as r tends to zero and as
r tends to infinity are also derived. The Darboux technique of intertwining
operators is then applied to obtain an algorithm that makes it possible to
solve the Schrodinger equation with a singular potential containing many
negative powers of r, if the exact solution with even just one term is already
known.Comment: 19 pages, plain Tex. In this revised version, the analysis of Eq.
(5.29) has been amended, and an appendix has been added for completenes
Risk factors for liver decompensation and hcc in hcv-cirrhotic patients after daas: A multicenter prospective study
Background: Prospective studies on predictors of liver-related events in cirrhotic subjects achieving SVR after DAAs are lacking. Methods: We prospectively enrolled HCV cirrhotic patients in four Italian centers between November 2015 and October 2017. SVR and no-SVR cases were compared according to the presence or absence of liver-related events during a 24-month follow-up. Independent predictors of liver-related events were evaluated by Cox regression analysis. Results: A total of 706 subjects started DAAs therapy. SVR was confirmed in 687 (97.3%). A total of 61 subjects (8.9%) in the SVR group and 5 (26.3%) in the no-SVR group had liver-related events (p < 0.03). The incidence rate x 100 p/y was 1.6 for HCC, 1.7 for any liver decompensation, and 0.5 for hepatic death. Baseline liver stiffness (LSM) ≥ 20 kPa (HR 4.0; 95% CI 1.1–14.1) and genotype different from 1 (HR 7.5; 95% CI 2.1–27.3) were both independent predictors of liver decompensation. Baseline LSM > 20 KPa (HR 7.2; 95% CI 1.9–26.7) was the sole independent predictor of HCC. A decrease in liver stiffness (Delta LSM) by at least 20% at the end of follow-up was not associated with a decreased risk of liver-related events. Conclusion: Baseline LSM ≥ 20 kPa identifies HCV cirrhotic subjects at higher risk of liver-related events after SVR
Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection.
Trends in prevalence of hepatitis B virus infection among Albanian blood donors, 1999-2009
<p>Abstract</p> <p>Background</p> <p>Hepatitis B virus (HBV) was among the first virus known to be transmitted by blood and blood productions. The objective of this study is to determine the trend of hepatitis B virus in blood donors.</p> <p>Materials and methods</p> <p>In this study 79274 blood donors were retrospectively evaluated for HBsAg. The donors were selected using personal questionnaire, physical examination and testing blood before donation. Blood banks records are used as source of information. The blood donors samples were analyzed for the presence of hepatitis B surface antigen (HBsAg) by commercial available kits ELISA method, third generation (from Abbott laboratory, Germany). A sample was considered as HBsAg positive when found twice repeatedly reactive. Reactive samples were not confirmed with addition tests.</p> <p>Results</p> <p>In the evaluation data, we found out that from 79274 of the total healthy blood donors, 15983 were voluntary donors, 52876 were family replacement donors and 10424 commercial blood donors. The prevalence of HBsAg in blood donors was 7.9%. It was increased steadily from 5.9% in 1999 to 9.1% in 2006 and decreased in 7.9% in 2009. According to blood donors status the HBsAg prevalence was 10.5% in commercial blood donors, 8.1% in voluntary donors and 8.6% in family replacement donors. The prevalence of anti-HBc in blood donors was 59.1%.</p> <p>Conclusion</p> <p>The prevalence of HBsAg was lower in voluntary non remunerate blood donors than commercial donors and family replacement blood donors. In FDs the prevalence was higher than VDs but lower than CDs. So, it is important to encourage the voluntary blood donors to become regularly blood donors.</p
Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
Background Hepatitis C virus (HCV) is a leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer, but little is known about the burden of disease caused by the virus. We summarised burden of disease data presently available for Europe, compared the data to current expert estimates, and identified areas in which better data are needed. Methods Literature and international health databases were systematically searched for HCV-specific burden of disease data, including incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and liver transplantation. Data were collected for the WHO European region with emphasis on 22 countries. If HCV-specific data were unavailable, these were calculated via HCV-attributable fractions. Results HCV-specific burden of disease data for Europe are scarce. Incidence data provided by national surveillance are not fully comparable and need to be standardised. HCV prevalence data are often inconclusive. According to available data, an estimated 7.3–8.8 million people (1.1–1.3%) are infected in our 22 focus countries. HCV-specific mortality, DALY, and transplantation data are unavailable. Estimations via HCV-attributable fractions indicate that HCV caused more than 86000 deaths and 1.2 million DALYs in the WHO European region in 2002. Most of the DALYs (95%) were accumulated by patients in preventable disease stages. About one-quarter of the liver transplants performed in 25 European countries in 2004 were attributable to HCV. Conclusion Our results indicate that hepatitis C is a major health problem and highlight the importance of timely antiviral treatment. However, data on the burden of disease of hepatitis C in Europe are scarce, outdated or inconclusive, which indicates that hepatitis C is still a neglected disease in many countries. What is needed are public awareness, co-ordinated action plans, and better data. European physicians should be aware that many infections are still undetected, provide timely testing and antiviral treatment, and avoid iatrogenic transmission
- …